This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
GYS1 / Glycogen [starch] synthase, muscle · IHC design guide
Design Immunohistochemistry for GYS1
GYS1 shows cytoplasmic staining in most tissues and is abundant in muscle cells (HPA tissue IHC). This paraffin IHC guide covers fixation consistency, chromogenic detection and interpretation of the tissue pattern.
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
GYS1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic in most tissues; abundant in muscle cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A03512-3) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation conditions consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Signal varies by tissue and cell type (HPA tissue IHC) | |
| Regulation | Muscle-cell abundance is high (HPA tissue IHC) | |
| Isoform / epitope | 2 isoforms; epitope coverage unspecified (UniProt) |
Section 1
Recommended GYS1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol (datasheet: A03512-3) is accompanied by published GYS1 staining protocols for breast cancer tissue and synovial tissue sections (PMC10242793; PMC6072843).
| Sample | Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A03512-3) |
| Fixation | Image fixative and duration unreported (datasheet A03512-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A03512-3); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A03512-3) |
| Primary antibody | Rabbit anti-GYS1, 2-5 μg/ml (datasheet A03512-3) |
| Primary incubation | Overnight at 4 °C (datasheet A03512-3) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A03512-3) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | GYS1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in most tissues, highly abundant in muscle cells. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval for the catalog antibody (datasheet: A03512-3). The breast cancer study reports heat retrieval without specifying a buffer (PMC10242793).
Section 2
What Is the Expected GYS1 Staining Pattern?
GYS1 staining should be predominantly cytoplasmic in paraffin sections, with particularly abundant staining in muscle cells (HPA tissue IHC: Enhanced; cytoplasmic profile). Skeletal muscle and other glycogen-containing cells are plausible positives (UniProt P13807: tissue specificity). GYS1 has no annotated transmembrane segment, so a membrane-restricted pattern would be unexpected (UniProt P13807: topology). HPA’s tissue assessment has medium agreement with RNA data and awaits external verification (HPA tissue IHC: reliability description).
| Strong cytoplasmic staining in muscle cells, with staining in other tissues. | This fits HPA’s highly abundant muscle-cell pattern and cytoplasmic expression in most tissues (HPA tissue IHC: profile). Compare cells within the section; broad expression means a second stained tissue is not, by itself, evidence of cross-reactivity (HPA tissue IHC: profile). |
| Signal is mainly nuclear or sharply confined to cell membranes. | This conflicts with the observed cytoplasmic tissue pattern (HPA tissue IHC: profile). GYS1 has no annotated transmembrane segment (UniProt P13807: topology). Review the counterstain, detection controls and cellular boundaries before scoring such signal as GYS1 (standard IHC practice). |
| Intense staining appears in a cell population reported as low. | HPA reports low staining in lung alveolar type II cells and bone-marrow hematopoietic cells; low does not mean absent (HPA tissue IHC: low entries). Unexpectedly strong signal warrants comparison with a positive tissue and detection controls for cross-reactivity or endogenous activity (standard IHC practice). |
| Weak, diffuse colour covers cells and surrounding tissue. | A haze that obscures cellular boundaries cannot establish cytoplasmic localisation (standard IHC practice). Assess a primary-antibody omission control and the counterstain for nonspecific detection or inadequate washing before assigning cell-specific GYS1 staining (standard IHC practice). |
| No staining is seen in skeletal muscle or another expected-positive sample. | Skeletal muscle is an expected positive based on tissue expression (UniProt P13807: tissue specificity; HPA tissue IHC: muscle-cell profile). An absent result is inconclusive until section quality, reagent performance and detection controls are checked (standard IHC practice). |
💡Expected GYS1 appearanceCall a result positive when muscle cells show clear, abundant cytoplasmic staining (HPA tissue IHC: profile); nuclear-only or membrane-only colour is inconsistent with the reported pattern (HPA tissue IHC: profile; UniProt P13807: topology).
| Tissue and cell selection | HPA reports high staining in colon glandular cells and bronchial respiratory epithelial cells, among others (HPA tissue IHC: positive entries). Its listed low cell populations are comparison points, not validated negatives (HPA tissue IHC: low entries; negative list empty). |
| IHC evidence strength | The overall tissue profile is rated Enhanced, but its antibody staining has medium agreement with RNA and awaits external verification (HPA tissue IHC: reliability description). HPA separately rates CAB007793 IHC Enhanced and HPA041598 IHC Supported (HPA antibodies: IHC validation). |
| Intracellular protein form | The annotated GYS1 chain spans residues 1–737, with no signal peptide or propeptide (UniProt P13807: processing). Its lack of an annotated transmembrane segment supports interpreting a membrane-only outline cautiously (UniProt P13807: topology). |
| Isoforms and modified residues | UniProt lists two isoforms and multiple phosphorylation sites (UniProt P13807: isoforms; modified residues). Neither source identifies this guide’s antibody epitope or establishes how those features alter IHC staining; do not infer isoform-specific staining from intensity alone. |
| IF/ICC Q: where should signal appear? | A: HPA reports cytosol and microtubules as approved ICC-IF locations, with images from A-431, U-251MG and U2OS (HPA subcellular: approved locations; image list). That cell-image result complements, but does not replace, the cytoplasmic tissue-IHC expectation (HPA tissue IHC: profile). |
| Situation | Likely cause | Next action |
|---|---|---|
| Muscle positive control has no visible signal. | The result cannot distinguish absent target from a failed staining run without controls (standard IHC practice). | Check section integrity, counterstain and detection controls; review antigen retrieval and antibody dilution against the validated IHC workflow (standard IHC practice). Do not assign a GYS1-specific retrieval failure: fixation sensitivity is unreported in the supplied sources. |
| Signal is nuclear or forms a crisp membrane rim. | The compartment differs from HPA’s cytoplasmic tissue profile (HPA tissue IHC: profile) and the approved ICC-IF cytosol/microtubule locations (HPA subcellular: approved locations). | Inspect cellular boundaries and counterstain, then compare a primary-antibody omission control (standard IHC practice). Treat compartment-mismatched colour as unresolved until controls support specificity. |
| Reported low-staining cells look as strong as nearby expected positives. | Low HPA entries are relative observations, not proof that staining must be absent (HPA tissue IHC: low entries). Cross-reactivity or endogenous detection activity is also possible (standard IHC practice). | Compare matched sections and a detection-only control; assess whether colour follows cell morphology or extends beyond cells (standard IHC practice). Avoid using a low HPA entry as an absolute negative control. |
| Colour is diffuse across tissue or the slide. | Diffuse deposit can result from nonspecific detection or insufficient washing (standard IHC practice); it does not demonstrate the cellular pattern HPA reports (HPA tissue IHC: profile). | Review blocking, washing and detection controls within the IHC workflow, then score only staining whose cell boundaries and cytoplasmic compartment can be resolved (standard IHC practice). |
| Two antibodies give different tissue patterns. | HPA assigns different IHC validation levels to CAB007793 and HPA041598 (HPA antibodies: IHC validation). Its overall tissue profile also awaits external verification (HPA tissue IHC: reliability description). | Compare the same tissue and cell populations with matched controls, and record each antibody’s pattern separately (standard IHC practice). Do not treat the overall Enhanced tissue rating as proof that both antibodies agree. |
| Staining is present outside muscle. | GYS1 is expressed in most other cell types where glycogen is present (UniProt P13807: tissue specificity); HPA also reports cytoplasmic expression in most tissues (HPA tissue IHC: profile). | Identify the stained cell population and compare its localisation with the HPA tissue profile and relevant cell-level entries (HPA tissue IHC: profile; positive entries). Judge unexpected intensity with controls before calling it false positive (standard IHC practice). |
Experiment evidence
IHC & IF images showing GYS1 staining
A03512-3 · IHCIHC analysis of Glycogen synthase 1/GYS1 using anti-Glycogen synthase 1/GYS1 antibody (A03512-3). Glycogen synthase 1/GYS1 was detected in a
A03512-3 · IHCIHC analysis of Glycogen synthase 1/GYS1 using anti-Glycogen synthase 1/GYS1 antibody (A03512-3). Glycogen synthase 1/GYS1 was detected in a
A03512-3 · IFIF analysis of Glycogen synthase 1/GYS1 using anti-Glycogen synthase 1/GYS1 antibody (A03512-3). Glycogen synthase 1/GYS1 was detected in an
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000104812-GYS1/tissue/cerebral+cortex#imid_2133408
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000104812-GYS1/tissue/colon#imid_2133334
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000104812-GYS1/tissue/liver#imid_2133335
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000104812-GYS1/tissue/kidney#imid_2133352
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA041598; green = GYS1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA041598; green = GYS1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for GYS1 IHC & IF
🧪Run breast tissue first and look for staining in glandular cells (HPA: High in breast glandular cells). HPA detects GYS1 in all 45 scored tissues, so there is no supported negative tissue; use no-primary and isotype controls, and expect cells without specific staining on the positive slide to show only background without assuming any cell type is GYS1-negative (HPA: no negative tissue rows).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: None in HPA: GYS1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show GYS1 in A-431, U-251MG, U2OS, with annotated localisation: Microtubules (approved), Cytosol (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only section and a concentration-matched rabbit isotype control alongside the positive section; use GYS1 knockout material, if available, or a validated immunizing-peptide block as a biological specificity control (selected-SKU caption: rabbit primary antibody). For chromogenic detection, check endogenous peroxidase and biotin background because the reported breast-tissue method uses biotinylated secondary antibody, streptavidin-biotin complex, and DAB (selected-SKU tissue-IHC caption).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the fixative used for the selected-SKU paraffin section is unreported (selected-SKU tissue-IHC caption). The reported IHC method uses heat retrieval in EDTA at pH 8.0, but the evidence does not establish whether retrieval is required for other conditions (selected-SKU tissue-IHC caption). Frozen sections cannot be judged easier from the supplied evidence; IF/ICC images exist, but they provide no comparative workflow evidence (HPA subcellular: ICC-IF images in A-431, U-251MG, and U2OS).
HPA tissue IHC evidence for GYS1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Cerebellum | Cells in molecular layer | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: GYS1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced GYS1 IHC Tips
Troubleshoot GYS1 staining in paraffin-section chromogenic IHC using the selected antibody’s tissue image, expression evidence and appropriate controls.
What retrieval should I try first when GYS1 staining is weak?
Begin with heat-mediated antigen retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A03512-3). The selected GYS1 tissue image used this retrieval before incubation with 2 μg/ml antibody overnight at 4°C (caption A03512-3). If staining is weak, check that heating and cooling were consistent across sections, then vary retrieval duration while holding buffer and antibody conditions constant (standard IHC practice). Compare each change with a concurrently processed positive control; stronger staining alone does not establish specificity, particularly when retrieval also increases diffuse background (standard IHC practice).
Could fixation explain weak or uneven GYS1 staining?
The selected image shows a paraffin-embedded section, but its fixative and fixation duration are unreported (caption A03512-3). GYS1-specific sensitivity to fixation therefore remains unknown; neither tissue expression patterns nor the protein’s phosphorylation sites establish a fixation effect (HPA tissue IHC; UniProt P13807 modified residues). Record the fixative, duration and processing history for each specimen, and compare sections processed together before changing antibody concentration (standard IHC practice). If signal varies across a block, inspect tissue preservation and repeat the documented EDTA pH 8.0 retrieval on matched sections with a positive control (datasheet A03512-3; standard IHC practice).
Where should convincing GYS1 staining appear in tissue sections?
Expect predominantly cytoplasmic tissue staining, with strong abundance reported in muscle cells (HPA tissue IHC). Cell imaging places GYS1 in the cytosol and on microtubules, although those finer structures may be difficult to resolve by chromogenic tissue IHC (HPA subcellular; standard IHC practice). GYS1 has no annotated transmembrane segment, so a crisp membrane-only pattern needs scrutiny rather than automatic acceptance (UniProt P13807 topology). Compare staining with cell morphology and a concurrently processed positive section; assess unexpected nuclear or extracellular signal against the no-primary control and local background before scoring it as GYS1 (standard IHC practice).
Can this antibody distinguish GYS1 isoforms or phosphorylation states?
The record lists 2 GYS1 isoforms and multiple modified residues, including phosphoserines at positions 8, 11, 412, 641 and 645 (UniProt P13807 isoforms; UniProt P13807 modified residues). The supplied tissue caption does not identify the antibody epitope or establish isoform or phosphorylation selectivity (caption A03512-3). Interpret chromogenic intensity as antibody reactivity under the tested retrieval and detection conditions, rather than as a direct measure of enzyme activity (standard IHC interpretation). To investigate an isoform or phosphorylation claim, obtain epitope validation and compare appropriate independently validated reagents on matched sections (standard IHC practice).
How should I assess GYS1 by IF alongside a cell-type marker?
For the separate IF/ICC application, pair GYS1 with a marker that identifies the expected cell type, and include single-stain controls to assess channel bleed-through (HPA tissue IHC; standard IF practice). Choose fluorophores after checking tissue autofluorescence in an unstained section; a far-red GYS1 channel can improve separation when shorter wavelengths show substantial background (standard IF practice). Permeabilise sufficiently for an intracellular epitope, since GYS1 is associated with the cytosol and microtubules and has no annotated transmembrane segment (HPA subcellular; UniProt P13807 topology). Optimise IF fixation and permeabilisation using IF controls because the paraffin-section caption supplies neither an IF workflow nor fixation evidence (caption A03512-3).
How can I reduce diffuse brown signal with this detection system?
The selected image used 10% goat serum blocking, a biotinylated secondary antibody, streptavidin–biotin detection and DAB chromogen (caption A03512-3). With that detection chemistry, compare a no-primary section and assess endogenous biotin and peroxidase activity before attributing diffuse brown staining to GYS1 (standard IHC practice). Apply an appropriate peroxidase block, check whether biotin blocking is needed, and keep DAB development consistent across test and control sections (standard IHC practice). If background persists, titrate the primary antibody below the caption’s 2 μg/ml condition while retaining a positive control and the same retrieval method (caption A03512-3; standard IHC practice).
What is a defensible way to score GYS1 IHC? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and score cytoplasmic signal only, consistent with the reported tissue pattern (HPA tissue IHC). An H-score combines the percentage of cells at each intensity grade from 0 to 3, giving a range of 0–300; alternatively, report the percentage of positive viable cells with a predefined threshold (standard IHC scoring practice). Normalise cell-based scores to the viable cells evaluated, or normalise positive-cell counts to tissue area in mm² when using density (standard IHC scoring practice). Keep retrieval, DAB development, imaging and threshold settings consistent, and report the counted compartments and excluded damaged regions (standard IHC practice).
How do I distinguish genuine GYS1 signal from tissue artefact?
A plausible result shows cytoplasmic staining in appropriate cells, with muscle-cell abundance supported by the tissue profile (HPA tissue IHC). Nuclear-only, sharply membrane-bound or extracellular deposits warrant review because GYS1 lacks an annotated transmembrane segment and cell imaging places it in the cytosol and on microtubules (UniProt P13807 topology; HPA subcellular). Compare suspicious staining at section edges or in necrotic regions with better-preserved tissue, and check a no-primary control for nonspecific DAB signal (standard IHC practice). With biotin-based detection, also assess endogenous biotin and peroxidase activity before calling persistent brown signal a true positive (caption A03512-3; standard IHC practice).
Boster reagents
Best GYS1 / Glycogen [starch] synthase, muscle IHC Antibodies
A03512-3 has IHC images from human paraffin sections and an IF image from A431 cells (A03512-3 image captions); the catalog lists human, mouse and rat reactivity (A03512-3 catalog).
Real IHC data
Anti-Glycogen synthase 1/GYS1 Antibody ®
Cat # A03512-3
A03512-3 has IHC images from human breast cancer, lymphoma, placenta and renal clear cell carcinoma sections, plus an IF image from A431 cells (A03512-3 image captions); its catalog lists human, mouse and rat reactivity (A03512-3 catalog). M03512 and M03512-2 are catalog-listed rabbit monoclonals for IHC and IF in human, mouse and rat, while P03512-2 is a catalog-listed rabbit monoclonal for phospho-GYS1 S641 IHC and IF in human and mouse; none has a supplied IHC or IF image (catalog payload).
Which to pick: Choose A03512-3 for paraffin-section IHC: its human tissue captions document EDTA retrieval at pH 8.0 and 2 μg/ml primary antibody; the fixative is unreported (A03512-3 IHC image captions). Choose A03512-3 for IF/ICC when an image-backed example matters: its A431 caption documents 5 μg/ml primary antibody (A03512-3 IF image caption). For a rabbit monoclonal with catalog-listed human, mouse and rat IHC/IF reactivity, consider M03512-2; its IHC processing conditions are undocumented in the supplied captions (M03512-2 catalog; M03512-2 IHC image alts).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P13807 (GYS1_HUMAN, Glycogen [starch] synthase, muscle).
- Human Protein Atlas. GYS1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. GYS1 subcellular location (ICC-IF): Localized to the cytosol and microtubules..
- Human Protein Atlas. GYS1 antibody validation summary (2 antibodies).
- Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer. Journal of experimental & clinical cancer research : CR 2023 — PMC10242793.
- Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2023 — PMC10684475.
- Multi-omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple-negative breast cancer. MedComm 2024 — PMC10901283.
- Glycogen Metabolism and Rheumatoid Arthritis: The Role of Glycogen Synthase 1 in Regulation of Synovial Inflammation via Blocking AMP-Activated Protein Kinase Activation. Frontiers in immunology 2018 — PMC6072843.
- PubMed PMID:2493642 — UniProt-cited evidence.
- PubMed PMID:7657035 — UniProt-cited evidence.
- PubMed PMID:9010351 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for GYS1 (Glycogen [starch] synthase, muscle). Expected localisation Cytoplasmic tissue staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A03512-3). Validated IHC antibody: A03512-3 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A03512-3); 2. Fixation: Image fixative and duration unreported (datasheet A03512-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A03512-3); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A03512-3); 8. Primary antibody: Rabbit anti-GYS1, 2-5 μg/ml (datasheet A03512-3); 9. Primary incubation: Overnight at 4 °C (datasheet A03512-3). Watch for: Fixation: Keep fixation conditions consistent across sections (standard IHC practice; not target-specific); Caveat: Signal varies by tissue and cell type (HPA tissue IHC); Isoform / epitope: 2 isoforms; epitope coverage unspecified (UniProt); Regulation: Muscle-cell abundance is high (HPA tissue IHC). Evidence: UniProt P13807, HPA tissue IHC · Enhanced, HPA ICC-IF · cytosol and microtubules., Datasheet A03512-3, PMC10242793, PMC6072843. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/GYS1/immunohistochemistry-ihc-guide.